Viracta Therapeutics Q2 EPS $(0.32) Misses $(0.28) Estimate
Portfolio Pulse from Happy Mohamed
Viracta Therapeutics reported Q2 losses of $0.32 per share, missing the analyst consensus estimate of $0.28 by 14.29%. This represents a 14.29% increase in losses compared to the same period last year.
August 14, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viracta Therapeutics' Q2 earnings missed analyst estimates, with losses increasing by 14.29% compared to the same period last year.
Viracta Therapeutics reported a larger than expected loss for Q2, missing analyst estimates. This is likely to negatively impact investor sentiment and could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100